

78027_Auto_EditedC.docx

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 78027

Manuscript Type: META-ANALYSIS

**Combining of chemotherapy with targeted therapy for advanced biliary tract cancer:
A systematic review and meta-analysis**

Bai XS *et al.* Targeted therapy in biliary tract cancer

Xue-Song Bai, Sheng-Nan Zhou, Yi-Qun Jin, Xiao-Dong He

Abstract

BACKGROUND

Targeted therapy (TT) has resulted in controversial efficacy as first-line treatment for biliary tract cancer (BTC). More efficacy comparisons are required to clarify the overall effects of chemotherapy (CT) combined with TT and CT alone on advanced BTC.

AIM

To conduct a meta-analysis of the available evidence on the efficacy of CT combined with TT for advanced BTC.

METHODS

The PubMed, EMBASE, ClinicalTrials, Scopus and Cochrane Library databases were systematically searched for relevant studies published from inception to August 2022. Only randomized clinical trials (RCTs) including comparisons between the combination of gemcitabine-based CT with TT and CT alone as first-line treatment for advanced BTC were eligible (PROSPERO-CRD42022313001). The odds ratios (ORs) for the objective response rate (ORR) and hazard ratios (HRs) for both progression-free survival (PFS)

and overall survival (OS) were calculated and analyzed. Subgroup analyses based on different targeted agents, CT regimens and tumor locations were prespecified.

RESULTS

Nine RCTs with a total of 1361 individuals were included and analyzed. The overall analysis showed a significant improvement in ORR in patients treated with CT + TT compared to those treated with CT alone (OR = 1.43, 95%CI: 1.11-1.86, $P = 0.007$) but no difference in PFS or OS. Similar trends were observed in the subgroup treated with agents targeting epidermal growth factor receptor (OR = 1.67, 95%CI: 1.17-2.37, $P = 0.004$) but not in the subgroups treated with agents targeting vascular endothelial growth factor receptor or mesenchymal-epithelial transition factor. Notably, patients who received a CT regimen of gemcitabine+oxaliplatin in the CT + TT arm had both a higher ORR (OR = 1.75, 95%CI: 1.20-2.56, $P = 0.004$) and longer PFS (HR = 0.83, 95%CI: 0.70-0.99, $P = 0.03$) than those in the CT-only arm. Moreover, patients with cholangiocarcinoma treated with CT + TT had significantly increased ORR and PFS (ORR, OR = 2.06, 95%CI: 1.27-3.35, PFS, HR = 0.79, 95%CI: 0.66-0.94).

CONCLUSION

CT + TT is a potential first-line treatment for advanced BTC that leads to improved tumor control and survival outcomes, and highlighting the importance of CT regimens and tumor types in the application of TT.

Key Words: Advanced biliary tract cancer; Targeted therapy; Chemotherapy; Meta-analysis; Randomized controlled trial; First-line treatment

Bai XS, Zhou SN, Jin YQ, He XD. Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis. *World J Gastrointest Oncol* 2022; In press

Core Tip: The clinical efficacy¹² of adding targeted agents to first-line treatment of biliary tract cancer (BTC) remains unclear. Our study is the first² meta-analysis of randomized clinical trials to evaluate the efficacy of the combination of targeted therapy (TT) with standard chemotherapy (CT)¹⁹ as first-line treatment in patients with advanced BTC. We assessed the efficacy of combined TT and CT in terms of objective response rate,³² progression-free survival and overall survival. Subgroup analyses were conducted based on different targeted agents, CT regimens and tumor locations.

INTRODUCTION

Biliary tract cancer (BTC), including cholangiocarcinoma (CCA) (intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma, or cholangiocarcinoma in the distal biliary tree) and gallbladder cancer (GBC), is a relatively rare invasive adenocarcinoma with a dismal prognosis. In recent decades, the incidence of BTC has shown a consistent increasing trend worldwide, particularly in Asian countries^[1]. Surgery offers the only potentially curative treatment option for patients who have resectable disease. The high incidence of lymph node involvement and liver invasion are associated with worse clinical outcomes after surgery. However, given the frequent absence of symptoms and late diagnosis in patients with BTC, only a minority of patients (35% for CCA and 20% for GBC) are potential candidates for radical resection; even after resection with a negative surgical margin, the postoperative relapse rate is over 60%^[2-4].

For patients with advanced BTC, including radically unresectable or metastatic adenocarcinoma^[5], the available systemic therapeutics have limited effect, with a five-year survival of 4%^[6,7]. Currently, the first-line treatment for advanced BTC remains gemcitabine-based chemotherapy regimens^[1]. According to the ABC-02 trial in 2010, gemcitabine and cisplatin combination chemotherapy (CisGem) was verified to improve overall survival (OS), progression-free survival (PFS) and tumor control rate (TCR) compared with gemcitabine monotherapy in patients with CCA and GBC^[6,8]. Gemcitabine and oxaliplatin (GemOx) combination therapy was also identified as an alternative to CisGem. The results of a phase III randomized controlled trial (RCT) in 2019 showed that modified GemOx might lead to a longer median OS ($P = 0.57$) and different toxicities than CisGem^[9]. In addition, randomized phase 3 study trials evaluating efficacy have shown that the efficacy of gemcitabine and S1 combination regimens are noninferior to that of CisGem^[10]. Nevertheless, no studies have verified if the superiority of such regimens over CisGem has statistical significance.

Due to the limited efficacy of current chemotherapy (CT) regimens for advanced BTC, new therapies need to be developed. In the past decade, through new parallel

sequencing of malignancies, several genetic alterations and molecular characteristics for BTC have been further revealed, including isocitrate dehydrogenase (IDH)-1 and -2 mutations, fibroblast growth factor receptor (FGFR) fusions, neurotropic tyrosine kinase receptor fusions, V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations and aberrations of human epidermal growth factor receptor (HER) family members^[11-14]. Targeted therapies (TTs) based on monoclonal antibodies or tyrosine kinase inhibitors associated with actionable genetic alterations in BTC are being extensively explored. Recently, combinations of CT and TT have been attempted to improve the prognosis for advanced BTC, but the clinical efficacy remains to be further evaluated^[15].

Considering that the high heterogeneity and low incidence of BTC impede the recruitment of large cohorts of patients to identify effective targets and regimens in clinical trials, meta-analysis is needed to further assess the value of TT and investigate the survival benefits of this treatment. This study is the first meta-analysis of RCTs to evaluate the efficacy of the combination of TT with standard CT as first-line treatment for patients with advanced BTC.

MATERIALS AND METHODS

This systematic review and meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement guidelines and was prospectively registered in The International Prospective Register of Systematic Reviews (PROSPERO, <https://www.crd.york.ac.uk/prospero/>) platform (registration number CRD42022313001).

Search strategy

A systematic literature search of the PubMed/MEDLINE, Clinical Trials, EMBASE, SOCPUS and Cochrane Library databases was conducted from inception to August 2022. Various combinations of the following search terms were used in the database searches: "biliary tract cancer", "gallbladder neoplasms", "cholangiocarcinoma",

"molecular targeted therapy" and "antineoplastic agents". Reference Citation Analysis (<https://www.referencecitationanalysis.com>) was used to avoid missing relevant studies. In addition, we searched the reference lists of the included literature and potentially relevant studies to retrieve studies from other sources. The detailed search strategy and results are described in the supplement (Supplementary Table 1).

Selection criteria

Trials were eligible for inclusion if they met the following criteria: (1) Randomized controlled trials involving patients with BTC who were treated with targeted therapy and chemotherapy as first-line treatment; and (2) Advanced, unresectable, recurrent or metastatic BTC with PFS, OS, and/or objective response rate (ORR) reported. Studies involving the following were excluded: (1) No standard chemotherapy arm as a control; (2) Case reports, reviews, commentaries, notes and letters; and (3) Non-English language articles. Two independent reviewers conducted the assessment of all the searched studies. To avoid duplicate clinical data, the registration information in ClinicalTrials.gov was checked, and the most recent and most complete publication was incorporated.

Data extraction and quality assessment

Two authors independently extracted the data and information. In the event of a disagreement, the data source was checked, and a third reviewer was consulted to confirm the correct data. The following information was extracted: the first author's name, journal name, publication year, study period, national clinical trial number, institution and country. The detailed demographic characteristics included the number of patients, age, sex and disease site. Regarding therapeutic interventions, information on the treatment regimen was collected. The efficacy outcomes extracted included the ORR, PFS and OS. If the hazard ratios (HRs) of OS or PFS were not reported in the literature, Engauge Digitizer 4.1 was used to plot points on the survival curves and extract the HR values.

⁷ The risk of bias and quality of the RCTs were assessed by two independent authors in accordance with the criterion of the Cochrane risk of bias tool (ROB) including the following seven dimensions: ¹blinding of participants and personnel (performance bias), ¹blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. A third author was consulted to resolve any disagreements.

⁴¹ **Statistical analysis**

Pooled HRs with 95% CIs were calculated for time-to-event data, including OS and PFS. Estimated odds ratios (ORs) were calculated for discrete variables, including the ORR and adverse events. The selection of ³⁸a fixed- or random-effects model was based ⁷on the level of heterogeneity of the data, which was assessed by Cochran's Q-test and the Higgins I^2 statistic. ²⁰A fixed effects model was adopted for $I^2 < 50\%$, and a random effect model was adopted for $I^2 > 50\%$. The potential bias of the publications was presented as funnel plots and measured using Egger's tests. ¹Subgroup analysis was performed based ³⁵on the different targets of the agents, CT regimens and location of the BTC. $P < 0.05$ was ⁵⁴considered statistically significant. All statistical analyses of the extracted data were conducted with Review Manager 5.4.1 (Cochrane Collaboration, Oxford, United Kingdom).

RESULTS

¹⁷ **Study search and selection**

The PRISMA flowchart of the study search and selection process is presented in Figure 1. A total of 1654 records were retrieved in the initial search of PubMed, Embase, Scopus, Cochrane ⁴⁴Library and ClinicalTrials.gov. A total of 621 records were duplicates and removed, and 1033 ¹records were screened for eligibility using titles and abstracts. Of the 32 studies that underwent full-text assessment, nine RCTs met the prespecified inclusion criteria for the meta-analysis^[16-24].

Study characteristics and quality assessment

The design characteristics of the nine clinical trials are summarized in Table 1. All 9 studies included were RCTs. Data on a total of 1361 patients were provided in the nine included trials. Eight targeted treatment regimens (ramucirumab, merestinib, panitumumab, cediranib, vandetanib, cetuximab, sorafenib and erlotinib) and three gemcitabine-based first-line CT regimens (CisGem, GemOx and gemcitabine) were used. Four of the studies were designed with blinding using CT plus placebo as comparators. All studies reported final data for ORR, PFS and OS as endpoints, with an acceptable sample size of patients and adequate length of follow-up. The quality assessment of the included articles was evaluated with the ROB (Supplementary Figure 1).

The descriptions of all the trial patients are presented in Table 2. Overall, the median age of the patients ranged from 59 to 68 years old. Most patients in these cohorts had unresectable disease with metastases. There was no difference between the CT group and CT combined with TT group in the distribution of age, sex, Eastern Cooperative Oncology Group performance status, disease status or primary tumor site.

Evaluation of efficacy

ORR: The ORR reported in the studies ranged from 19.3% to 44% in the CT + TT group and 10% to 39% in the CT group (Figure 2A). No significant heterogeneity was detected among studies, with $I^2 = 44\%$ and $P = 0.06$. Therefore, the fixed-effect model was adopted for the meta-analysis. The pooled data showed that CT + TT could significantly increase the ORR in BTC compared to CT (OR = 1.43, 95%CI: 1.11-1.86, $P = 0.007$). Subgroup analyses showed heterogeneity between different targeting molecules ($I^2 = 60.5\%$, $P = 0.05$), implying that different therapeutic targets might an interaction effect on the ORR of BTC patients. CT + TT targeting for epidermal growth factor receptor (EGFR) might more effectively enhance the ORR in BTC than CT alone (Figure 2B, OR = 1.67, 95%CI: 1.17-2.37, $P = 0.004$), but no difference was found for agents targeting vascular endothelial growth factor receptor (VEGFR) ($P = 0.29$), mesenchymal-epithelial

transition factor (MET) ($P = 0.09$) or VEGFR/EGFR ($P = 0.41$). No significant heterogeneity was detected in the ORR among subgroups of different CT regimens ($I^2 = 14.5\%$, $P = 0.31$). In the GemOx subgroup, the ORR was higher in the CT + TT arm than in the CT-only arm (Figure 2C, OR = 1.75, 95%CI: 1.20-2.56, $P = 0.004$).

PFS: The median PFS ranged from 4.1 to 8.25 mo in the CT-only group and 3.0 to 8.0 mo in the CT combined with TT group. The overall pooled HR for OS was calculated based on a fixed-effect model ($I^2 = 32\%$, $P = 0.15$). The results showed that the BTC patients in the group treated with CT + TT had a longer PFS than those treated with CT alone, but this difference was not statistically significant (Figure 3A, HR = 0.96, 95%CI: 0.85-1.08, $P = 0.47$). In the subgroup analysis, the selection of different CT regimens was found to have an interaction effect on PFS in BTC patients ($I^2 = 70.0\%$, $P = 0.04$). When the CT regimen was GemOx, a remarkable survival benefit was observed in the CT + TT group compared to the CT-only group (HR = 0.83, 95%CI: 0.70-0.99, $P = 0.03$). Similar to the ORR results, when targeting EGFR, the combination of CT with TT still tended to lead to better PFS for BTC patients, although no statistical significance was observed (OR = 0.88, 95%CI: 0.75-1.03, $P = 0.11$) ($P = 0.59$ when targeting VEGFR, $P = 0.21$ when targeting VEGFR/EGFR, $P = 0.49$ when targeting MET).

OS: The median OS ranged from 9.5 to 20.07 mo in the CT-only group and 8.4 to 14.1 mo in the CT combined with TT group. Except for the Santoro *et al*^[21] study, all of the studies reported OS with HR data and events as outcomes. The fixed-effect model was applied, with $I^2 = 0\%$ and $P = 0.53$. The pooled data showed no significant improvement in the OS of BTC patients treated with CT + TT compared to those treated with CT alone (Figure 4A, HR = 1.04, 95%CI: 0.92-1.19, $P = 0.50$). Subgroup analysis among different molecular targets and CT regimens failed to show differences between CT and CT + TT (both $I^2 = 0\%$).

Exploratory analysis

Exploratory analyses were performed to compare the effect of combining CT with TT according to the site of tumor origin (Figure 5). Among the 9 studies, two studies differentiated the data of PFS for GBC from BTC. Four studies reported PFS data for CCA [iCCA or extrahepatic cholangiocarcinoma (eCCA)]. After data pooling, heterogeneity was detected among subgroups in PFS according to tumor location ($I^2 = 78.4\%$, $P = 0.03$), with no significant heterogeneity within subgroups (both $I^2 = 0\%$). In the subgroup of patients with CCA, CT + TT conferred an improved ORR and PFS benefit compared to CT alone (ORR: OR = 2.06, 95%CI: 1.27, 3.35, $P = 0.003$; PFS: HR = 0.79, 95%CI: 0.66-0.94, $P = 0.010$). In contrast, the ORR and PFS did not differ among patients with GBC (ORR: $p = 0.77$, PFS: $P = 0.30$). The OS was similar between the CT and CT + TT groups for both CCA and GBC patients.

Assessment of publication bias

Publication bias was assessed by Egger's test and is presented as a funnel plot. Both the P value from Egger's test and the symmetry seen from the funnel plot indicate that there was no evidence of significant publication bias for ORR, PFS or OS in our meta-analysis (Figure 6, Egger's test, $P = 0.756, 0.171, 0.706$, respectively).

DISCUSSION

BTC tends to be diagnosed late and is associated with a poor prognosis. Currently, gemcitabine-based CT is still the standard first-line treatment for unresectable advanced BTC. However, the median survival in gemcitabine-treated BTC patients is only approximately 12 mo^[13]. To further improve patient prognosis, more effective first-line strategies need to be explored^[25]. Therefore, riple CT combinations such as with the addition of S-1 or nab-paclitaxel to the standard of care CisGem, 5-fluorouracil, irinotecan and oxaliplatin as well as some new agents such as NUC-1031 have also been evaluated in phase 2 clinical trials and demonstrated favorable safety profile^[26-28]. Thereinto, gemcitabine, cisplatin plus S-1 showed survival benefits and higher risk ratio than gemcitabine, cisplatin. However, further exploration is required with phase III

clinical trials for improving the clinical outcomes of advanced BTC patients. Recently, with the further understanding and exploration of the molecular characteristics of BTC, several actionable mutations have been identified and have changed the treatment paradigm for BTC. Currently, inhibitors targeting FGFR fusions and IDH-1 and -2 mutations have been tested in clinical trials with encouraging outcomes for pretreated CCA. As one of the most promising targets, the survival benefit of IDH-1 inhibitors as a second-line treatment option in IDH-1-mutated CCA has been demonstrated in a phase III clinical trial^[29]. In addition, some pre-clinical and early clinical studies on other potential targets including HER-2, BRAF and ring finger protein 43 mutations are currently undertaken^[30]. However, their efficacy as first-line treatment for BTC is still being evaluated in ongoing clinical trials (NCT02386397). Due to the lack of adequate patient selection, whether the addition of TT to first-line treatment improves prognosis compared with CT alone has been controversial to date.

This analysis pooled and analyzed data from a total of 1361 individuals from 9 RCTs to compare the effects of CT with TT or CT alone, in terms of the ORR, PFS and OS, as BTC treatment. Our results suggest that combination TT with CT as first-line systemic treatment for advanced biliary tract malignancies might be associated with beneficial outcomes in some situations.

Overall, our meta-analysis showed a significant improvement in the ORR in unselected patients treated with CT + TT compared to that in patients treated with CT (28.6% vs 20.7%). All the trials included adopted gemcitabine-based CT schedules for first-line systemic therapy, which is consistent with the current standards of care. Therefore, the ORR of CisGem was superior to that of gemcitabine alone, similar to in the phase III ABC-02 study^[6]. Oxaliplatin is sometimes substituted for cisplatin. The adoption of GemOx as first-line CT is based on the fact that oxaliplatin is easier to administer than cisplatin, as it does not require excessive hydration and reduces the risk of renal toxicity, but maintains a similar efficacy to CisGem^[6,31,32]. However, there has been no direct comparison or validated superiority among different combinations (CisGem and GemOx) in advanced BTC. Our results demonstrate that combination TT

with CT might significantly improve the ORR in BTC patients treated with GemOx (27.4% vs 17.7%, $P = 0.004$)⁵². Moreover, a similar significant advantage was observed in PFS for combination TT with CT, which we regard as a more unbiased outcome than OS, because OS is susceptible to the influence of subsequent therapies and other factors (HR = 0.83, $P = 0.03$)^[33].

In the subgroup analysis of GemOx, the main driver of the OS benefit favoring the combination of TT and CT was the data from the study from Lee *et al*^[24], in which erlotinib plus GemOx yielded a clear improvement in ORR (30% vs 15.8, $P = 0.005$) and a marginal superiority in PFS (5.8 mo vs 4.2 mo, HR = 0.80, 95%CI: 0.61-1.03, $P = 0.087$)⁴ compared with GemOx alone. Similar to our results, the PFS improved significantly with cetuximab plus gemcitabine treatment (HR = 0.66, 95%CI: 0.45-0.98, $P = 0.04$)²⁹ in the study by Chen *et al*^[20] that included Chinese patients. Unlike the other studies in this subgroup, Chen *et al*^[20] adopted the modified GemOx regimen, which might have a better compliance rate than traditional GemOx GemOx, and observed a significantly longer treatment duration for GemOx plus cetuximab than for GemOx alone ($P = 0.01$). These results suggest that relatively mild CT regimens plus TT might be advantageous and beneficial for advanced BTC patients, especially Asian patients.

The heterogeneity of different anatomical locations and molecular profiles has been demonstrated to be associated with differences in clinicopathologic features and prognoses of advanced BTC. However, complete information about treatment and survival is usually absent in classifications that are based on molecular subtypes and anatomical location^[34]. The subgroup analysis showed that the combination of EGFR agents with CT significantly improved the ORR compared with CT alone (30.3% vs 19.5%, $P = 0.004$)¹, but no significant difference in PFS or OS was observed between the two groups. These results corroborate the finding of a pooled analysis by Eckel *et al*^[35] that analyzed pooled data from 161 trials containing 6337 BTC patients treated with gemcitabine-based CT with or without TT¹⁵. The study also demonstrates that the combination of EGFR-targeted agents with gemcitabine-based CT was more effective

for tumor control and survival, with superior outcomes in the TCR, tumor progression and OS.

Nevertheless, most of the RCTs (except for the study from Chen *et al*^[20]) could not independently validate a significant improvement with the combination of TT with CT. Given that differences in survival outcomes and molecular profiling have been reported between GBC and non-GBC BTCs, an exploratory analysis based on different tumor locations was conducted^[6,36,37]. Previous studies have shown that patients with CCA tend to exhibit better chemosensitivity and prognoses than those with GBC^[38]. Interestingly, in our meta-analysis, both the ORR and PFS in the iCCA and eCCA subgroups improved with the combination treatment of TT with CT (*vs* CT alone) ($P = 0.003$, $P = 0.010$, respectively), but no difference in ORR or PFS was observed for the GBC subgroup (combination of TT with CT *vs* CT alone). Our results suggest that CCA might be associated with better treatment response and survival outcomes than GBC. Due to the different characteristics and patterns of CCA and GBC, more clinical data evaluating tumor location-specific outcomes should be reported in the future.

⁵⁷ **Limitations**

There are some potential limitations in our study. First, due to our strict inclusion criteria, only nine studies were included in the meta-analysis. Even so, the nearly symmetrical funnel plot and Egger's test indicated no evidence of publication bias. Second, the proportion of BTCs was imbalanced in terms of tumor location, which might have implications for overall tumor control and survival outcomes. Furthermore, the detailed data for subgroups of tumor location were incomplete, which might also influence the quality of the evaluation for overall outcomes. Moreover, the gender ratio, age and countries of patients were assumed to be similar, although they varied among the included studies. In addition, only English studies were included, which might result in a risk of language bias.

CONCLUSION

18

In conclusion, this meta-analysis provides supporting clinical evidence for the promise of TT as first-line systemic therapy for advanced BTC. Gemcitabine-based CT combined with TT, especially agents targeting EGFR, could evidently increase the ORR for advanced BTC compared to CT alone. However, the higher ORR did not appear to translate into a significant benefit in PFS or OS in most of the prospective trials. Despite this, we identified that the CT regimen and tumor location had significant interactions in assessing the effect of TT in advanced BTC. CT combined with TT significantly improved the survival outcome of advanced BTC in patients who received GemOx as first-line treatment or those with CCA but not GBC. A deeper understanding of TT is required and the results are promising for the development of novel treatment strategies for advanced BTC. Our results help facilitate the design of future clinical trials for advanced BTC.

4

ARTICLE HIGHLIGHTS

Research background

The prognosis of patients with advanced biliary tract cancer (BTC) is poor. The clinical efficacy of combining chemotherapy (CT) with targeted therapy (TT) as first-line treatment remains controversial.

Research motivation

Currently, TT based on actionable genetic alterations in BTC are being extensively explored. However, the clinical efficacy of combination CT with TT as first-line treatment for advanced BTC is unclear. A meta-analysis is necessary to systematically and comprehensively evaluate the clinical value of TT for advanced BTC.

Research objectives

The purpose of this meta-analysis was to explore the value of CT combined with TT as first-line treatment for advanced BTC.

Research methods

We systematically searched PubMed, EMBASE, ClinicalTrials, Scopus, and the Cochrane Library databases to screen and include randomized clinical trials (RCTs) on gemcitabine-based CT alone *vs* the combination of TT and CT as first-line treatment for advanced BTC. Review Manager 5.4.1 software was used to conduct the statistical analysis. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were analyzed as main outcomes. Subgroup analyses based on different targeted agents, CT regimens and tumor locations were performed.

Research results

Our meta-analysis showed a significant improvement in ORR in patients treated with CT + TT compared to those treated with CT alone ($P = 0.007$), but no difference in PFS or OS. Similar trends were observed in the subgroup treated with agents targeting EGFR ($P = 0.004$). Notably, patients who received a CT regimen of gemcitabine + oxaliplatin in the CT + TT arm had both a higher ORR ($P = 0.004$) and longer PFS ($P = 0.03$) than those in the CT-only arm. Moreover, patients with cholangiocarcinoma treated with CT + TT had significantly increased ORR and PFS.

Research conclusions

Our study is the first meta-analysis of RCTs to evaluate the efficacy of the combining TT with standard CT as first-line treatment for advanced BTC. The meta-analysis has demonstrated that CT + TT is a promising first-line treatment for advanced BTC that leads to improved clinical outcomes.

Research perspectives

In the future, more clinical studies are needed to explore the role of TT for advanced BTC. In addition, attention should be paid on the interactions of CT regimen and tumor location for assessing the clinical efficacy of TT in advanced BTC.

27%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.ncbi.nlm.nih.gov Internet	140 words — 3%
2	www.science.gov Internet	120 words — 3%
3	worldwidescience.org Internet	57 words — 1%
4	www.wjgnet.com Internet	52 words — 1%
5	Angela Lamarca, Jorge Barriuso, Mairéad G. McNamara, Juan W. Valle. "Molecular targeted therapies: ready for "prime time" in biliary tract cancer", Journal of Hepatology, 2020 Crossref	43 words — 1%
6	academic.oup.com Internet	38 words — 1%
7	link.springer.com Internet	36 words — 1%
8	Heng Liu, Qi-Di Zhang, Zheng-Hong Li, Qing-Qing Zhang, Lun-Gen Lu. "Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis", World Journal of Gastroenterology, 2014	34 words — 1%

-
- 9 www.frontiersin.org 32 words — 1%
Internet
-
- 10 Xu Yang, Dongxu Wang, Jianzhen Lin, Jianping Xiong et al. "Abstract 4992: The occurrence of immune-related adverse events indicates better efficacy of immune checkpoint blockade in solid tumors: A systematic review and meta-analysis", Cancer Research, 2019 31 words — 1%
Crossref
-
- 11 cyberleninka.org 31 words — 1%
Internet
-
- 12 Sheng Zhao, Yanping Miao, Ruijun Wang, Haidong Guo, Feng Jin, Xiuling Guo, Tianyou Luo. "Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis", OncoTargets and Therapy, 2016 27 words — 1%
Crossref
-
- 13 Hua-Yang Pang, Xian-Wen Liang, Xiao-Long Chen, Quan Zhou et al. "Assessment of indocyanine green fluorescence lymphography on lymphadenectomy during minimally invasive gastric cancer surgery: a systematic review and meta-analysis", Surgical Endoscopy, 2022 26 words — 1%
Crossref
-
- 14 wclc2022.iaslc.org 26 words — 1%
Internet
-
- 15 Amartej Merla, Kenneth G. Liu, Lakshmi Rajdev. "Targeted Therapy in Biliary Tract Cancers", Current Treatment Options in Oncology, 2015 23 words — 1%
Crossref

-
- 16 Ruijuan Chen, Yongkai Lu, Yuemei Zhang, Ruixin He, Fengwen Tang, Wei Yuan, Yi Li, Xiaowei Zhang. 23 words — 1%
"Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma", Medicine, 2021
Crossref
-
- 17 Sanjay Beesoon, Beate C. Sydora, Nguyen X. Thanh, David Chakravorty et al. "Does the Introduction of American College of Surgeons NSQIP Improve Outcomes? A Systematic Review of the Academic Literature", Journal of the American College of Surgeons, 2020 23 words — 1%
Crossref
-
- 18 docksci.com 21 words — < 1%
Internet
-
- 19 Xiaofeng Chen, Xiaofeng Wu, Hao Wu, Yanhong Gu et al. "Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial", Journal for ImmunoTherapy of Cancer, 2020 19 words — < 1%
Crossref
-
- 20 journals.lww.com 19 words — < 1%
Internet
-
- 21 "Posters", Hepatology, 2020 17 words — < 1%
Crossref
-
- 22 files.covid19treatmentguidelines.nih.gov 17 words — < 1%
Internet
-
- 23 www.dovepress.com 17 words — < 1%
Internet

24 Christopher D. Jakubowski, Nilofer S. Azad. "Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)", Chinese Clinical Oncology, 2020

Crossref

16 words — < 1%

25 www.biochemia-medica.com

Internet

15 words — < 1%

26 e-sciencecentral.org

Internet

14 words — < 1%

27 9dok.org

Internet

13 words — < 1%

28 Liwei Ni, Jian Wu, Yuming Long, Xuya Yuan, Jianhao Xu, Jialong Tao, Runhong Wu, Na Yu, Yusong Zhang. "Mortality of site-specific cancer in patients with schizophrenia: A systematic review and meta-analysis", Research Square Platform LLC, 2019

Crossref Posted Content

13 words — < 1%

29 cadth.ca

Internet

13 words — < 1%

30 Teng-Kai Yang, Ya-Fang Yu, Hsing-Ju Li, Kai-Wen Huang, Chia-Hsien Cheng Jason. "Efficacy and Safety of Combined Targeted Therapy and Immunotherapy versus Targeted monotherapy in Unresectable Hepatocellular Carcinoma: A Systematic review and Meta- Analysis", Research Square Platform LLC, 2022

Crossref Posted Content

12 words — < 1%

31 Zhou, Zhi-Rui, Shi-Xin Liu, Tian-Song Zhang, Ling-Xiao Chen, Jun Xia, Zhi-De Hu, and Bo Li. "Short-course preoperative radiotherapy with immediate surgery

12 words — < 1%

versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: A systematic review and meta-analysis", Surgical Oncology, 2014.

Crossref

-
- | | | |
|----|---|-----------------|
| 32 | aging-us.com
<small>Internet</small> | 12 words — < 1% |
|----|---|-----------------|
-
- | | | |
|----|---|-----------------|
| 33 | encyclopedia.pub
<small>Internet</small> | 12 words — < 1% |
|----|---|-----------------|
-
- | | | |
|----|---|-----------------|
| 34 | pesquisa.bvsalud.org
<small>Internet</small> | 12 words — < 1% |
|----|---|-----------------|
-
- | | | |
|----|--|-----------------|
| 35 | Yu, Wei-Wei, Yan-Mei Guo, Qing Zhang, and Shen Fu. "Benefits from adjuvant intraoperative radiotherapy treatment for gastric cancer: A meta-analysis", Molecular and Clinical Oncology, 2014.
<small>Crossref</small> | 11 words — < 1% |
|----|--|-----------------|
-
- | | | |
|----|---|-----------------|
| 36 | researchers.general.hokudai.ac.jp
<small>Internet</small> | 11 words — < 1% |
|----|---|-----------------|
-
- | | | |
|----|--|-----------------|
| 37 | Evridiki K. Vouloumanou, Eleni Plessa, Drosos E. Karageorgopoulos, Elpis Mantadakis, Matthew E. Falagas. "Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis", Intensive Care Medicine, 2011
<small>Crossref</small> | 10 words — < 1% |
|----|--|-----------------|
-
- | | | |
|----|---|-----------------|
| 38 | www.bristol.ac.uk
<small>Internet</small> | 10 words — < 1% |
|----|---|-----------------|
-
- | | | |
|----|---|-----------------|
| 39 | www.cancercare.on.ca
<small>Internet</small> | 10 words — < 1% |
|----|---|-----------------|
-

40 Ferdinando De Vita. "Clinical management of advanced gastric cancer: The role of new molecular drugs", World Journal of Gastroenterology, 2014 9 words — < 1%
Crossref

41 Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu. "Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis", Frontiers in Oncology, 2022 9 words — < 1%
Crossref

42 Tian Sun, Hao Xu, Fengqin Xu. "Astragalus Injection for Hypertensive Renal Damage: A Systematic Review", Evidence-Based Complementary and Alternative Medicine, 2012 9 words — < 1%
Crossref

43 Zhen Wang, Jun-qiang Chen, Jin-lu Liu, Xin-gan Qin, Yuan Huang. "Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review", BMC Gastroenterology, 2012 9 words — < 1%
Crossref

44 digitalcommons.mcmaster.ca 9 words — < 1%
Internet

45 jcancer.org 9 words — < 1%
Internet

46 pubmed.ncbi.nlm.nih.gov 9 words — < 1%
Internet

47 www.ajmc.com 9 words — < 1%
Internet

48 www.hindawi.com

9 words — < 1%

49 Ali Belkouz, Tim A. Labeur, Joeri Dierks, Frederike Dijk et al. "Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis", Critical Reviews in Oncology/Hematology, 2019

Crossref

8 words — < 1%

50 Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh et al. "Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review", Cancer Research and Treatment, 2017

Crossref

8 words — < 1%

51 Na Li, Meilan Yang, Ke Shi, Wei Li. "Long non-coding RNA HOXA11-AS in human cancer: A meta-analysis", Clinica Chimica Acta, 2017

Crossref

8 words — < 1%

52 Nicholas G. Murray, V. N. Pradeep Ambati, Monica M. Contreras, Anthony P. Salvatore, Rebecca J. Reed-Jones. "Assessment of oculomotor control and balance post-concussion: A preliminary study for a novel approach to concussion management", Brain Injury, 2014

Crossref

8 words — < 1%

53 Www.dovepress.com

Internet

8 words — < 1%

54 downloads.hindawi.com

Internet

8 words — < 1%

55 www.Clinicaltrials.gov

Internet

8 words — < 1%

- 56

www.healio.com
Internet

8 words — < 1%
- 57

www.nature.com
Internet

8 words — < 1%
- 58

Eiichiro Suzuki, Junji Furuse, Masafumi Ikeda, Takuji Okusaka et al. "Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases", Oncology, 2010
Crossref

6 words — < 1%
- 59

Marco Dubois, Nicole Liscia, Oronzo Brunetti, Pina Ziranu et al. "The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials", Critical Reviews in Oncology/Hematology, 2022
Crossref

6 words — < 1%
- 60

Shengjie Sun, Huiyu Dong, Tao Yan, Junchen Li, Chao Liang, Bianjiang Liu, Pengfei Shao, Jie Li. "Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis", Research Square Platform LLC, 2020
Crossref Posted Content

6 words — < 1%

EXCLUDE QUOTES OFF
EXCLUDE BIBLIOGRAPHY OFF

EXCLUDE SOURCES OFF
EXCLUDE MATCHES OFF